CA2623795C - Methods and constructs for analyzing biological activities of biological specimens and determining states of organism - Google Patents
Methods and constructs for analyzing biological activities of biological specimens and determining states of organism Download PDFInfo
- Publication number
- CA2623795C CA2623795C CA2623795A CA2623795A CA2623795C CA 2623795 C CA2623795 C CA 2623795C CA 2623795 A CA2623795 A CA 2623795A CA 2623795 A CA2623795 A CA 2623795A CA 2623795 C CA2623795 C CA 2623795C
- Authority
- CA
- Canada
- Prior art keywords
- activities
- reporter
- cells
- cultured
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004071 biological effect Effects 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000012472 biological sample Substances 0.000 claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims description 122
- 230000000694 effects Effects 0.000 claims description 78
- 102000040945 Transcription factor Human genes 0.000 claims description 47
- 108091023040 Transcription factor Proteins 0.000 claims description 47
- 238000013518 transcription Methods 0.000 claims description 39
- 230000035897 transcription Effects 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 14
- 230000002103 transcriptional effect Effects 0.000 claims description 14
- 108010042407 Endonucleases Proteins 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 108091062157 Cis-regulatory element Proteins 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 210000004251 human milk Anatomy 0.000 claims description 3
- 235000020256 human milk Nutrition 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 210000001179 synovial fluid Anatomy 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 210000003061 neural cell Anatomy 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 9
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 230000010632 Transcription Factor Activity Effects 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 29
- 241000700159 Rattus Species 0.000 description 29
- 239000000523 sample Substances 0.000 description 27
- 108091027981 Response element Proteins 0.000 description 16
- 230000004075 alteration Effects 0.000 description 16
- 108010057466 NF-kappa B Proteins 0.000 description 15
- 102000003945 NF-kappa B Human genes 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 13
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 12
- 229960001052 streptozocin Drugs 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 108700012920 TNF Proteins 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- -1 CAT Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 238000012287 DNA Binding Assay Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 102100026792 Aryl hydrocarbon receptor Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000012896 Statistical algorithm Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72186005P | 2005-09-28 | 2005-09-28 | |
| US60/721,860 | 2005-09-28 | ||
| PCT/US2006/038175 WO2007038756A2 (en) | 2005-09-28 | 2006-09-27 | Methods and constructs for analyzing biological activities of biological specimens and determining states of organism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2623795A1 CA2623795A1 (en) | 2007-04-05 |
| CA2623795C true CA2623795C (en) | 2016-06-14 |
Family
ID=37900495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2623795A Expired - Fee Related CA2623795C (en) | 2005-09-28 | 2006-09-27 | Methods and constructs for analyzing biological activities of biological specimens and determining states of organism |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100009348A1 (enExample) |
| EP (1) | EP1945795B1 (enExample) |
| JP (1) | JP5346583B2 (enExample) |
| CA (1) | CA2623795C (enExample) |
| WO (1) | WO2007038756A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2430579A2 (en) * | 2009-05-11 | 2012-03-21 | Koninklijke Philips Electronics N.V. | Device and method for comparing molecular signatures |
| GB201002130D0 (en) * | 2010-02-10 | 2010-03-31 | Tmri Ltd | Cell based bioassay |
| US20120245048A1 (en) * | 2011-03-25 | 2012-09-27 | Institute For Systems Biology | Cellular response assay for biofluid biomarker discovery and detection |
| CN103930566B (zh) * | 2011-09-08 | 2018-01-26 | 埃塔格尼公司 | 用于测定水中生物污染物的系统和方法 |
| US20140323341A1 (en) * | 2011-09-08 | 2014-10-30 | Attagene, Inc. | Systems and methods for assessment of biosimilarity |
| WO2014121104A1 (en) * | 2013-01-31 | 2014-08-07 | The Regents Of The University Of California | Pooled genetic perturbation effects |
| JP2021078370A (ja) * | 2019-11-15 | 2021-05-27 | 国立大学法人大阪大学 | 全身性エリトマトーデスの治療薬に対するコンパニオン診断薬 |
| EP4399523A4 (en) * | 2021-09-07 | 2025-02-19 | Mayo Foundation for Medical Education and Research | Methods and materials for determining pgc target dosage |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625048A (en) * | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US5928868A (en) * | 1996-04-26 | 1999-07-27 | Massachusetts Institute Of Technology | Three hybrid screening assay |
| EP1141359B1 (en) * | 1998-12-17 | 2006-10-04 | Xenogen Corporation | Non-invasive evaluation of physiological response in a mammal |
| GB2355791B (en) * | 1999-10-28 | 2004-10-20 | Molecular Light Tech Res Ltd | Detection of mRNA expression using chemiluminescent labelled probes |
| US6867348B1 (en) * | 1999-12-16 | 2005-03-15 | Xenogen Corporation | Methods and compositions for screening for angiogenesis modulating compounds |
| CA2327581A1 (en) * | 2000-12-27 | 2002-06-27 | Yves Blais | Methods and compositions for the establishment of genetically altered cell-based library designed for monitoring transcriptional activity of compounds and molecules |
| US20020177218A1 (en) * | 2001-03-30 | 2002-11-28 | Yu Fang | Methods of detecting multiple DNA binding protein and DNA interactions in a sample, and devices, systems and kits for practicing the same |
| AU2002314927A1 (en) * | 2001-06-06 | 2002-12-16 | Cogent Neuroscience, Inc. | Nucleic acid regulatory sequences and uses therefor |
| US20030143547A1 (en) * | 2002-01-24 | 2003-07-31 | Xianqiang Li | Method for identifying multiple activated transcription factors |
| US20030148287A1 (en) * | 2002-01-24 | 2003-08-07 | Xianqiang Li | Libraries and kits for detecting transcription factor activity |
| DE10211063A1 (de) * | 2002-03-13 | 2003-10-09 | Axaron Bioscience Ag | Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo |
| WO2004094653A2 (en) * | 2003-04-22 | 2004-11-04 | Irm Llc | Differential tag length analysis of cell proliferation |
| US20050181354A1 (en) * | 2004-02-18 | 2005-08-18 | Estep Preston W.Iii | Methods of assaying physiological states |
| JP5301160B2 (ja) * | 2004-11-10 | 2013-09-25 | アッタゲネ インコーポレーテッド | レポーター配列の集団及びそれらの使用方法 |
-
2006
- 2006-09-27 JP JP2008533695A patent/JP5346583B2/ja not_active Expired - Fee Related
- 2006-09-27 US US11/992,900 patent/US20100009348A1/en not_active Abandoned
- 2006-09-27 CA CA2623795A patent/CA2623795C/en not_active Expired - Fee Related
- 2006-09-27 WO PCT/US2006/038175 patent/WO2007038756A2/en not_active Ceased
- 2006-09-27 EP EP06825268.3A patent/EP1945795B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009509545A (ja) | 2009-03-12 |
| WO2007038756A9 (en) | 2015-10-15 |
| EP1945795A4 (en) | 2010-01-13 |
| US20100009348A1 (en) | 2010-01-14 |
| WO2007038756A2 (en) | 2007-04-05 |
| EP1945795A2 (en) | 2008-07-23 |
| JP5346583B2 (ja) | 2013-11-20 |
| EP1945795B1 (en) | 2016-08-10 |
| CA2623795A1 (en) | 2007-04-05 |
| WO2007038756A3 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gold et al. | RORα coordinates reciprocal signaling in cerebellar development through sonic hedgehog and calcium-dependent pathways | |
| Tenenbaum et al. | Identifying mRNA subsets in messenger ribonucleoprotein complexes by using cDNA arrays | |
| US8143002B2 (en) | Methods for isolating and characterizing endogenous mRNA-protein (mRNP) complexes | |
| Charbord et al. | In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR | |
| AU2025234250A1 (en) | Methods For the Treatment of Solid Tumor Cancers using Illudins and Biomarkers | |
| Govey et al. | Mapping the osteocytic cell response to fluid flow using RNA-Seq | |
| Liu et al. | miR-155-5p is negatively associated with acute pancreatitis and inversely regulates pancreatic acinar cell progression by targeting rela and Traf3 | |
| CA2623795C (en) | Methods and constructs for analyzing biological activities of biological specimens and determining states of organism | |
| Sandovici et al. | Ageing is associated with molecular signatures of inflammation and type 2 diabetes in rat pancreatic islets | |
| Boeckel et al. | SLM2 is a novel cardiac splicing factor involved in heart failure due to dilated cardiomyopathy | |
| Chen et al. | NT5C2 methylation regulatory interplay between DNMT1 and insulin receptor in type 2 diabetes | |
| Morcillo et al. | The effect of metabolic and bariatric surgery on DNA methylation patterns | |
| Glineur et al. | Assessment of a urinary kidney microRNA panel as potential nephron segment-specific biomarkers of subacute renal toxicity in preclinical rat models | |
| JPWO2020180741A5 (enExample) | ||
| Zhong et al. | Multiplexed digital detection of B-cell acute lymphoblastic leukemia fusion transcripts using the NanoString nCounter system | |
| Yoshioka et al. | Fluorescence laser microdissection reveals a distinct pattern of gene activation in the mouse hippocampal region | |
| Sayad et al. | PIAS genes as disease markers in bipolar disorder | |
| Bramswig et al. | Transcriptional and epigenetic regulation in human islets | |
| Hoffman et al. | Hydrophobic sand is a viable method of urine collection from the rat for extracellular vesicle biomarker analysis | |
| Okada et al. | Multi-functional regulation of 4E-BP gene expression by the Ccr4-Not complex | |
| Maley et al. | Multiplexed RT-PCR for high throughput screening applications | |
| Engel et al. | Differences in chromatin accessibility between renal cortex and inner medulla correlate with spatial differences in gene expression and are modulated by NFAT5 function | |
| Lange et al. | Molecular methods for gene expression analysis: ecotoxicological applications | |
| Zhang et al. | Electrochemical sensor medical diagnosis assisted simulation LINC00115 exerts oncogenic function in triple negative breast cancer via regulation of TM9SF | |
| Liu et al. | standR: a Bioconductor package for analysing transcriptomic Nanostring GeoMx DSP data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210927 |
|
| MKLA | Lapsed |
Effective date: 20210927 |